Your browser doesn't support javascript.
loading
Hypertrophic pachymeningitis in ANCA-associated vasculitis: a cross-sectional and multi-institutional study in Japan (J-CANVAS).
Shimojima, Yasuhiro; Kishida, Dai; Ichikawa, Takanori; Kida, Takashi; Yajima, Nobuyuki; Omura, Satoshi; Nakagomi, Daiki; Abe, Yoshiyuki; Kadoya, Masatoshi; Takizawa, Naoho; Nomura, Atsushi; Kukida, Yuji; Kondo, Naoya; Yamano, Yasuhiko; Yanagida, Takuya; Endo, Koji; Hirata, Shintaro; Matsui, Kiyoshi; Takeuchi, Tohru; Ichinose, Kunihiro; Kato, Masaru; Yanai, Ryo; Matsuo, Yusuke; Nishioka, Ryo; Okazaki, Ryota; Takata, Tomoaki; Ito, Takafumi; Moriyama, Mayuko; Takatani, Ayuko; Miyawaki, Yoshia; Ito-Ihara, Toshiko; Kawaguchi, Takashi; Kawahito, Yutaka; Sekijima, Yoshiki.
Afiliação
  • Shimojima Y; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan. yshimoji@shinshu-u.ac.jp.
  • Kishida D; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Ichikawa T; Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.
  • Kida T; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Yajima N; Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Omura S; Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Nakagomi D; Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan.
  • Abe Y; Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan.
  • Kadoya M; Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan.
  • Takizawa N; Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan.
  • Nomura A; Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
  • Kukida Y; Department of Rheumatology, Japanese Red Cross Society Kyoto Daini Hospital, Kyoto, Japan.
  • Kondo N; Department of Nephrology, Kyoto Katsura Hospital, Kyoto, Japan.
  • Yamano Y; Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan.
  • Yanagida T; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
  • Endo K; Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
  • Hirata S; Department of General Internal Medicine, Tottori Prefectural Central Hospital, Tottori, Japan.
  • Matsui K; Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
  • Takeuchi T; Department of Diabetes, Endocrinology and Clinical Immunology, Hyogo Medical University School of Medicine, Nishinomiya, Hyogo, Japan.
  • Ichinose K; Department of Internal Medicine (IV), Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Kato M; Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Yanai R; Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Matsuo Y; Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
  • Nishioka R; Department of Rheumatology, Tokyo Kyosai Hospital, Tokyo, Japan.
  • Okazaki R; Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
  • Takata T; Department of Rheumatology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
  • Ito T; Division of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
  • Moriyama M; Division of Gastroenterology and Nephrology, Tottori University, Yonago, Japan.
  • Takatani A; Division of Nephrology, Shimane University Hospital, Izumo, Shimane, Japan.
  • Miyawaki Y; Department of Rheumatology, Shimane University Faculty of Medicine, Izumo, Shimane, Japan.
  • Ito-Ihara T; Rheumatic Disease Center, Sasebo Chuo Hospital, Nagasaki, Japan.
  • Kawaguchi T; Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
  • Kawahito Y; The Clinical and Translational Research Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Sekijima Y; Department of Practical Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
Arthritis Res Ther ; 24(1): 204, 2022 08 23.
Article em En | MEDLINE | ID: mdl-35999568
ABSTRACT

BACKGROUND:

This study investigated the characteristics of hypertrophic pachymeningitis (HP) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), using information from a multicenter study in Japan.

METHODS:

We analyzed the clinical information of 663 Asian patients with AAV (total AAV), including 558 patients with newly diagnosed AAV and 105 with relapsed AAV. Clinical findings were compared between patients with and without HP. To elucidate the relevant manifestations for HP development, multivariable logistic regression analyses were additionally performed.

RESULTS:

Of the patients with AAV (mean age, 70.2 ± 13.5 years), HP was noted in 30 (4.52%), including 20 (3.58%) with newly diagnosed AAV and 10 (9.52%) with relapsed AAV. Granulomatosis with polyangiitis (GPA) was classified in 50% of patients with HP. A higher prevalence of GPA was significantly observed in patients with HP than in those without HP in total AAV and newly diagnosed AAV (p < 0.001). In newly diagnosed AAV, serum proteinase 3 (PR3)-ANCA positivity was significantly higher in patients with HP than in those without HP (p = 0.030). Patients with HP significantly had ear, nose, and throat (ENT) (odds ratio [OR] 1.48, 95% confidence interval [CI] 1.03-2.14, p = 0.033) and mucous membrane/eye manifestations (OR 5.99, 95% CI 2.59-13.86, p < 0.0001) in total AAV. Moreover, they significantly had conductive hearing loss (OR 11.6, 95% CI 4.51-29.57, p < 0.0001) and sudden visual loss (OR 20.9, 95% CI 5.24-85.03, p < 0.0001).

CONCLUSION:

GPA was predominantly observed in patients with HP. Furthermore, in newly diagnosed AAV, patients with HP showed significantly higher PR3-ANCA positivity than those without HP. The ear and eye manifestations may be implicated in HP development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Granulomatose com Poliangiite / Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Meningite Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Granulomatose com Poliangiite / Vasculite Associada a Anticorpo Anticitoplasma de Neutrófilos / Meningite Tipo de estudo: Observational_studies / Prevalence_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2022 Tipo de documento: Article